Abstract
Introduction

The identification of novel molecular targets for cancer therapy has led to a paradigm shift in drug development, with more emphasis placed now on small molecules that can effectively inhibit signalling pathways deregulated in cancer cells. Of the many survival pathways activated by cancer cells, hypoxic cell signalling has attracted significant interest for a number of years, based on the assumption that normal tissues do not experience the same extreme variations in oxygen levels present in the tumour microenvironment. Cancer cells are exposed to a gradient of oxygen levels that fluctuate in time and space, which trigger the activation of survival pathways that are not usually induced in normal tissues and that can be potentially targeted for therapeutic purposes
.
The discovery of hypoxia inducible factor (HIF)-1 in the early 1990s provided a molecular target associated with intratumour hypoxia that could be used for the development of novel cancer therapeutics [2] . Despite the intrinsic challenges associated with the discovery and development of pharmacological inhibitors of transcription factors, more so in the absence of structural information that could facilitate drug design, many academic groups and pharmaceutical companies have attempted to identify HIF-1 inhibitors [3] [4] [5] [6] . For the most part, efforts have been based on high throughput screening assays aimed at identification of inhibitors of HIF-1 expression and/or transcriptional activity [4] . After 
Mechanisms of action of HIF-1 inhibitors
An ever increasing number of agents are constantly being reported that inhibit HIF-1␣ expression and/or activity. We will attempt to discuss these agents based on their putative mechanism of action (Fig. 1 
Inhibitors of HIF-1␣ mRNA expression
HIF-1␣ accumulation is controlled primarily at the level of protein degradation or protein translation and most of the HIF-1␣ inhibitors identified so far target these pathways. However, it has also been suggested that, under hypoxic conditions, levels of HIF-1␣ mRNA may be a limiting factor affecting the rate of protein translation [7] and it is presumable that small molecule inhibitors might affect HIF-1␣ mRNA expression [8] and as a consequence the rate of HIF-1 translation. An interesting approach that might add specificity to HIF-1␣ inhibition is the use of an antisense oligonucleotide targeting HIF-1␣ (EZN-2698) [9]. EZN-2968 is highly specific and binds HIF-1␣ mRNA with high affinity causing its down-regulation and consequent reduction of HIF-1␣ protein levels, both in vitro and in vivo. Treatment with EZN-2968 results in tumour cell growth inhibition, down-regulation of HIF-1␣ target genes and impaired ability of HUVEC cells to form tubes in vitro. In vivo, EZN-2968 administration decreased endogenous HIF-1␣ and vascular endothelial growth factor (VEGF) mRNA levels in the liver of normal mice and showed antitumour activity in xenograft models of human prostate cancer (DU145). Preliminary results of ongoing phase I clinical trials in patients with advanced solid tumours indicate that EZN-2968 can be given safely and that potential activity has been observed in one patient with metastatic renal cell carcinoma (RCC). Future studies will be required to address a main limitation of antisense oligonucleotide approaches, which is the delivery to tumour tissues.
Another [10] [11] [12] , receptor tyrosine kinase [13] [14] [15] , cyclin-dependent kinase [16] , oncogenic pathways [17] [18] [19] [20] [21] 
Inhibitors of HIF-1␣ protein translation
Although the mechanism(s) underlying hypoxic regulation HIF-1␣ translation are still poorly understood, several agents have been described that may affect the rate of HIF-1␣ protein synthesis, including but not limited to inhibitors of topoisomerase I and II
Cardiac glycosides are another class of agents that have been recently reported to affect HIF-1␣ protein translation. In particular digoxin was identified as a potent inhibitor of HIF-1 activity in a cell-based screen of a chemical library of FDA approved agents [31]. Digoxin inhibited the translation of HIF-1␣ by an mTOR-independent mechanism and showed antitumour activity in xenograft models. Interestingly, digoxin inhibited tumour growth in established PC3 and P493-Myc tumour xenografts, yet did not affect the growth of xenografts expressing a constitutively active form of HIF-1␣, implicating HIF-1 in the antitumour activity of digoxin. Interestingly, digoxin, which is routinely used for the treatment of heart failure and arrhythmias, is currently being tested in a phase I clinical trial as a potential anticancer agent. Consistent with these results, fractionation of an organic solvent extract of the plant Crossosoma bigelovii led to the discovery of a new strophanthidin glycoside that also inhibited HIF-1 transcriptional activity [32]. Whether cardiac glycosides may effectively be used to inhibit HIF-1 in cancer patients, in the absence of unacceptable adverse events, remains to be established. Another HIF-1 inhibitor currently in phase I clinical trials in patients with advanced metastatic cancer is PX-478. This agent showed remarkable antitumour activity in a variety of human tumour xenograft models, which seemed to correlate with levels of expression of HIF-1␣ [33]. PX-478 inhibited constitutive and hypoxia-induced HIF-1␣ expression in a pVHL and p53 independent fashion. The inhibition seems to occur at multiple levels, since three different mechanisms have been proposed that might contribute to the decrease of HIF-1␣ accumulation. Indeed, it has been suggested that PX-478 inhibits HIF-1␣ deubiquitination, leading to increased degradation of polyubiquitinated HIF-1␣, reduces HIF-1␣ mRNA expression and also affects HIF-1␣ translation [34]. Results of an ongoing phase I trial should be available in the near future and might provide interesting information regarding antitumour activity and modulation of HIF-1␣ levels in cancer patients.
A signalling pathway that has been implicated in growth factor-dependent induction of HIF-1␣ translation is mTOR [35, 36] [46] . HIF-1␣ protein stability is also affected by its interaction with Hsp90. In the presence of Hsp90 inhibitors HIF-1␣ undergoes VHL-independent proteasomal degradation [47] ; moreover HIF-1␣ heterodimers may not acquire the proper conformation and fail to recruit cofactors important for HIF-1-mediated transcriptional activity [48] . The development of Hsp90 inhibitors started with the discovery of the natural product galdanamycin, a benzoquinone ansamycin antibiotic that inhibits Hsp90 by competing with the ATP binding site. Galdanamycin was found to induce HIF-1␣ degradation under both hypoxic and normoxic conditions in several cell lines [49] 
Inhibitors that affect HIF-1␣ degradation pathway
Hsp90 is a molecular chaperone that controls the folding and regulates the function of different client proteins, including receptor tyrosine kinases, serine/threonine kinases, transcription factors and activated oncoproteins
Inhibitors of HIF-1␣ transcriptional activity
Chetomin was originally identified as an inhibitor of HIF-1 transcriptional activity by interfering with the interaction of HIF-1␣
with the co-activator p300 [58] . However, because of toxicity the development of chetomin has not been further pursued.
Inhibition of the proteasome leads to normoxic accumulation of HIF-1␣ [59] . Paradoxically, HIF-1␣ that accumulates in the presence of proteasome blockade is transcriptionally inactive [60] . Bortezomib (PS-341) is a proteasome inhibitor FDA approved for treatment of patients with multiple myeloma and patients with mantle cell lymphoma who had received at least one prior therapy [61, 62] . Interestingly, the antitumour activity of bortezomib may correlate with its ability to repress HIF-1␣ transcriptional activity [63] . At low nanomolar concentrations bortezomib was able to impair the p300-HIF-1␣ interaction, by enhancing the binding of FIH to HIF-1␣ [64] . FIH is a dioxygenase that hydroxylates Asn803 in the C-terminal transactivation domain of HIF-1␣, thus preventing the recruitment of the co-activator p300. Interestingly, the concentrations of bortezomib able to inhibit HIF-1␣ activity are much lower than those required to impair proteasome function, suggesting that the mechanism of HIF inhibition by bortezomib may be independent from proteasome inhibition [65] . 
Conclusions
